To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06839872
Title A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (BOSS)
Acronym BOSS
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
Research Site Saint Petersburg Florida 33709 United States Details
Research Site Ames Iowa 50010 United States Details
Research Site Baltimore Maryland 21201 United States Details
Research Site Charlotte North Carolina 28204 United States Details
Research Site Winston-Salem North Carolina 27103 United States Details
Research Site Columbus Ohio 43210 United States Details
Research Site Medford Oregon 97504 United States Details
Research Site Nashville Tennessee 37203 United States Details
Research Site Charlottesville Virginia 22908 United States Details
Research Site Richmond Virginia 23219 United States Details
Research Site Seattle Washington 98109 United States Details
Research Site Spokane Washington 99208 United States Details
Research Site Tacoma Washington 98405 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field